|
Press Releases |
|
|
|
Tuesday, April 26, 2022 |
|
Legend Capital Portfolio: Korean Medical AI Company Lunit to List on KOSDAQ in 2Q2022 |
Legend Capital's portfolio company Lunit, a Korean Medical AI company, recently announced a preliminary approval from the Korea Exchange for initial public offering (IPO) on the KOSDAQ market, and it plans to submit a registration statement within the second quarter of 2022. more info >> |
|
Sunday, April 24, 2022 |
|
君联资本联合创建企业朗信生物遗传性视网膜变性基因治疗产品在中国获批临床 |
君联资本联合创建企业朗信生物(Innostellar Biotherapeutics Co.,Ltd)旗下上海朗昇生物科技有限公司宣布,公司产品LX101注射液用于治疗RPE65双等位基因突变相关的遗传性视网膜变性(IRD)患者的临床试验申请,已获得中国国家药品监督管理局药品审评中心(CDE)批准。 more info >> |
|
君聯資本聯合創建企業朗信生物遺傳性視網膜變性基因治療產品在中國獲批臨床 |
君聯資本聯合創建企業朗信生物(Innostellar Biotherapeutics Co.,Ltd)旗下上海朗昇生物科技有限公司宣佈,公司產品LX101注射液用於治療RPE65雙等位基因突變相關的遺傳性視網膜變性(IRD)患者的臨床試驗申請,已獲得中國國家藥品監督管理局藥品審評中心(CDE)批准。 more info >> |
|
Legend Capital's Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China |
Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics more info >> |
|
Thursday, April 7, 2022 |
|
君联资本所投创新型疫苗领军企业瑞科生物在港交所成功上市 |
3月31日,君联资本所投创新型疫苗领军企业瑞科生物(股票代码:02179.HK)在港交所成功上市。此次在港上市,成为“香港HPV疫苗第一股”、“香港新型佐剂疫苗第一股”的瑞科生物相信将会给香港资本市场注入新的活力。 more info >> |
|
君聯資本所投創新型疫苗領軍企業瑞科生物在港交所成功上市 |
3月31日,君聯資本所投創新型疫苗領軍企業瑞科生物(股票代碼:02179.HK)在港交所成功上市。此次在港上市,成為「香港HPV疫苗第一股」、「香港新型佐劑疫苗第一股」的瑞科生物相信將會給香港資本市場注入新的活力。 more info >> |
|
Legend Capital's Portfolio Company Recbio Lists on HKEX Successfully |
On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange. more info >> |
|
Tuesday, March 8, 2022 |
|
从边缘走向舞台中央:君联资本所投生物技术产业链上游专精特新企业的奋斗之路 |
据联想控股微空间报导,「专精特新」的灵魂是创新,强调「专精特新」就是要鼓励创新。政策目标在于强化科技创新和产业链供应链韧性,加强基础研究,推动应用研究,开展补链强链专项行动,加快解决「卡脖子」难题。联想控股旗下君联资本不仅有幸参与到众多「专精特新」企业的发展中,也践行着将「前瞻性」及「硬科技」作为关键词的投资理念。 more info >> |
|
從邊緣走向舞台中央:君聯資本所投生物技術產業鏈上游專精特新企業的奮鬥之路 |
據聯想控股微空間報導,「專精特新」的靈魂是創新,強調「專精特新」就是要鼓勵創新。政策目標在於強化科技創新和產業鏈供應鏈韌性,加強基礎研究,推動應用研究,開展補鏈強鏈專項行動,加快解決「卡脖子」難題。聯想控股旗下君聯資本不僅有幸參與到眾多「專精特新」企業的發展中,也踐行著將「前瞻性」及「硬科技」作為關鍵字的投資理念。 more info >> |
|
Thursday, March 3, 2022 |
|
Inceptio Technology Completes Financing of US$188 Million, Jointly Led by Legend Capital |
On 28 February 2022, Inceptio Technology, an autonomous driving truck technology and operation company, announced its completion of a US$188 million Series B+ equity financing, jointly led by Legend Capital. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Finerca Celebrates Milestone of 10,000 Clients with Launch of Exclusive Master Course in CFD Trading
Mar 29, 2024 06:48: JST
|
|
|
Avance Clinical은 세계 백신 대회에서 최신 백신 임상시험 뉴스를 공유합니다. 이 중에는 HIV-1 연구도 포함됩니다
Mar 29, 2024 06:42 HKT/SGT
|
|
|
Avance Clinical將在世界疫苗大會上分享最新的疫苗臨床試驗新聞,包括HIV-1研究
Mar 29, 2024 06:33 HKT/SGT
|
|
|
Avance Clinical将在世界疫苗大会上分享最新的疫苗临床试验新闻,包括HIV-1研究
Mar 29, 2024 06:22 HKT/SGT
|
|
|
703-Carat L'Heure Bleu Tanzanite Carving Sets New GUINNESS WORLD RECORDS(TM) Title as World's Largest Cut Tanzanite
Mar 29, 2024 06:00 HKT/SGT
|
|
|
Finerca Celebrates Milestone of 10,000 Clients with Launch of Exclusive Master Course in CFD Trading
Mar 29, 2024 05:36 HKT/SGT
|
|
|
Atlas Lithium Secures US$ 30,000,000 Strategic Investment and Offtake Agreement from Mitsui
Mar 28, 2024 19:09 HKT/SGT
|
|
|
王朝酒业公布2023年全年业绩
Mar 28, 2024 17:45 HKT/SGT
|
|
|
王朝酒業公佈2023年全年業績
Mar 28, 2024 17:42 HKT/SGT
|
|
|
Dynasty Fine Wines Announces 2023 Annual Results
Mar 28, 2024 17:35 HKT/SGT
|
|
|
东软教育:内生高质量发展 数字化赋能打开长远增长空间
Mar 28, 2024 16:45 HKT/SGT
|
|
|
東軟教育:內生高質量發展 數字化賦能打開長遠增長空間
Mar 28, 2024 16:42 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System
Mar 28, 2024 16:45 JST
|
|
|
浙江沪杭甬:业绩稳健向好 积极回馈股东 分红总额增长17.7%
Mar 28, 2024 15:43 HKT/SGT
|
|
|
浙江滬杭甬:業績穩健向好 積極回饋股東 分紅總額增長17.7%
Mar 28, 2024 15:37 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|